Skip to main content

Table 1 The overall distribution of the patients in different stages in our stratification groups of Fig. 5(d)

From: Integration of molecular features with clinical information for predicting outcomes for neuroblastoma patients

 

Stage 1

(n = 10)

Stage 2

(n = 21)

Stage 3

(n = 33)

Stage 4 s

(n = 16)

Stage 4

(n = 159)

Group 1

0%

0%

0%

37.5%

47%

Group 2

60%

52%

100%

6%

0%

Group 3

30%

0%

0%

6%

37%

Group 4

0%

48%

0%

37.5%

0%

Group 5

10%

0%

0%

13%

16%